Literature DB >> 26377725

Paediatric cardiovascular clinical trials: an analysis of ClinicalTrials.gov and the Food and Drug Administration Pediatric Drug Labeling Database.

Kevin D Hill1, Heather T Henderson1, Christoph P Hornik1, Jennifer S Li1.   

Abstract

Recent regulatory initiatives in the United States of America and Europe have transformed the paediatric clinical trials landscape by significantly increasing capital investment and paediatric trial volume. The purpose of this manuscript was to review the impact of these initiatives on the paediatric cardiovascular trials landscape when compared with other paediatric sub-specialties. We also evaluate factors that may have contributed to the success or failure of recent major paediatric cardiovascular trials so as to inform the optimal design and conduct of future trials in the field.

Entities:  

Keywords:  Pediatric cardiovascular trials; heart failure; pediatric exclusivity

Mesh:

Year:  2015        PMID: 26377725      PMCID: PMC4591024          DOI: 10.1017/S1047951115000980

Source DB:  PubMed          Journal:  Cardiol Young        ISSN: 1047-9511            Impact factor:   1.093


  20 in total

1.  An update on the therapeutic orphan.

Authors:  J T Wilson
Journal:  Pediatrics       Date:  1999-09       Impact factor: 7.124

2.  Clinical trial registration: a statement from the International Committee of Medical Journal Editors.

Authors:  Catherine De Angelis; Jeffrey M Drazen; Frank A Frizelle; Charlotte Haug; John Hoey; Richard Horton; Sheldon Kotzin; Christine Laine; Ana Marusic; A John P M Overbeke; Torben V Schroeder; Hal C Sox; Martin B Van Der Weyden
Journal:  N Engl J Med       Date:  2004-09-08       Impact factor: 91.245

3.  Future of pediatric therapeutics: reauthorization of BPCA and PREA.

Authors:  R M Ward; R Kauffman
Journal:  Clin Pharmacol Ther       Date:  2007-04       Impact factor: 6.875

4.  Economic return of clinical trials performed under the pediatric exclusivity program.

Authors:  Jennifer S Li; Eric L Eisenstein; Henry G Grabowski; Elizabeth D Reid; Barry Mangum; Kevin A Schulman; John V Goldsmith; M Dianne Murphy; Robert M Califf; Daniel K Benjamin
Journal:  JAMA       Date:  2007-02-07       Impact factor: 56.272

Review 5.  Problems in Hodgkin's disease management.

Authors:  A C Aisenberg
Journal:  Blood       Date:  1999-02-01       Impact factor: 22.113

6.  Single-dose pharmacokinetics of sotalol in a pediatric population with supraventricular and/or ventricular tachyarrhythmia.

Authors:  J P Saul; M S Schaffer; P P Karpawich; C C Erickson; M R Epstein; A P Melikian; J Shi; A H Karara; B Cai; P H Hinderling
Journal:  J Clin Pharmacol       Date:  2001-01       Impact factor: 3.126

7.  The Best Pharmaceuticals for Children Act of 2002: the rise of the voluntary incentive structure and congressional refusal to require pediatric testing.

Authors:  Lauren Hammer Breslow
Journal:  Harvard J Legis       Date:  2003

8.  Off-label drug use in hospitalized children.

Authors:  Samir S Shah; Matthew Hall; Denise M Goodman; Pamela Feuer; Vidya Sharma; Crayton Fargason; Daniel Hyman; Kathy Jenkins; Marjorie L White; Fiona H Levy; James E Levin; David Bertoch; Anthony D Slonim
Journal:  Arch Pediatr Adolesc Med       Date:  2007-03

9.  Pediatric antihypertensive trial failures: analysis of end points and dose range.

Authors:  Daniel K Benjamin; P Brian Smith; Pravin Jadhav; Jogarao V Gobburu; M Dianne Murphy; Vic Hasselblad; Carissa Baker-Smith; Robert M Califf; Jennifer S Li
Journal:  Hypertension       Date:  2008-03-10       Impact factor: 10.190

10.  Carvedilol for children and adolescents with heart failure: a randomized controlled trial.

Authors:  Robert E Shaddy; Mark M Boucek; Daphne T Hsu; Robert J Boucek; Charles E Canter; Lynn Mahony; Robert D Ross; Elfriede Pahl; Elizabeth D Blume; Debra A Dodd; David N Rosenthal; Jeri Burr; Bernie LaSalle; Richard Holubkov; Mary Ann Lukas; Lloyd Y Tani
Journal:  JAMA       Date:  2007-09-12       Impact factor: 56.272

View more
  3 in total

1.  Pediatric Heart Network Trial of Losartan vs. Atenolol in Children and Young Adults with Marfan Syndrome: Impact on Prescription Practices.

Authors:  Dwight M Robertson; Dongngan T Truong; Daniel A Cox; Harris L Carmichael; Zhining Ou; L LuAnn Minich; Richard V Williams; E Seda Selamet Tierney
Journal:  Pediatr Cardiol       Date:  2022-07-28       Impact factor: 1.838

2.  Impact of COVID-19 disease on clinical research in pediatric and congenital cardiology.

Authors:  V Pommier; H Abassi; K Lavastre; J Calderon; S Guillaumont; Y Dulac; F Auriol; C Ovaert; A Blondelon; S Hascoet; F Lecerf; C Jore; M Avesani; J-B Thambo; P Amedro
Journal:  Arch Pediatr       Date:  2022-04-20       Impact factor: 1.820

3.  Serum circulating proteins from pediatric patients with dilated cardiomyopathy cause pathologic remodeling and cardiomyocyte stiffness.

Authors:  Danielle A Jeffrey; Julie Pires Da Silva; Anastacia M Garcia; Xuan Jiang; Anis Karimpour-Fard; Lee S Toni; Thomas Lanzicher; Brisa Peña; Carissa A Miyano; Karin Nunley; Armin Korst; Orfeo Sbaizero; Matthew Rg Taylor; Shelley D Miyamoto; Brian L Stauffer; Carmen C Sucharov
Journal:  JCI Insight       Date:  2021-10-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.